NCT06129526View on ClinicalTrials.gov

Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Diabetes Type 2HypertriglyceridemiaDiabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

EPAVasc

EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol

DIETARY_SUPPLEMENT

Corn Oil

Corn Oil

Trial Locations (1)

45110

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina

Sponsors
All Listed Sponsors
collaborator

LIBYTEC Pharmaceutical S.A.

UNKNOWN

lead

University of Ioannina

OTHER